KALA BIO Appoints Avi Minkowitz as New CEO and CFO Amidst Ongoing Financial Challenges

summarizeSummary

KALA BIO, Inc. announced the resignation of its CEO and CFO, David Lazar, and the immediate appointment of Avi Minkowitz to both roles, signaling a leadership change during a critical period for the company.

check_boxKey Events

• CEO and CFO Resignation

  David Lazar resigned from his roles as Chief Executive Officer and Chief Financial Officer, effective February 2, 2026. He will remain a director on the Board.

• New CEO and CFO Appointed

  Avi Minkowitz, a current director, was appointed as the new Chief Executive Officer and Chief Financial Officer, effective February 2, 2026.

• New Executive's Relevant Experience

  Mr. Minkowitz brings experience in financing for publicly traded companies, M&A, business development, and management consulting focused on growth, restructuring, and financing, which is highly relevant given KALA BIO's recent challenges.

• Context of Leadership Change

  This executive transition occurs shortly after KALA BIO secured highly dilutive financing and received shareholder approval for a reverse stock split, following a Nasdaq non-compliance notice regarding its minimum bid price.

auto_awesomeAnalysis

KALA BIO, a company facing significant financial distress and Nasdaq compliance issues, has replaced its Chief Executive Officer and Chief Financial Officer. The appointment of Avi Minkowitz, who has experience in financing, M&A, and restructuring, suggests a strategic move to address the company's precarious situation. This leadership change follows a series of highly dilutive financing activities and a Nasdaq non-compliance notice, indicating the board's intent to navigate the company through its current challenges. Investors will be watching to see if this new leadership can stabilize the company and improve its financial standing.